Related references
Note: Only part of the references are listed.Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
Monika Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
Juan J. Gomez-Reino et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study
Etienne Gayat et al.
PHARMACEUTICAL STATISTICS (2012)
Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
Henrik Christian Leffers et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety
Kazuki Yoshida et al.
RHEUMATOLOGY (2011)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry
Roberto Caporali et al.
AUTOIMMUNITY REVIEWS (2010)
TNF-alpha Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice
Antonio Marchesoni et al.
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY (2009)
The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis
Marlies Blom et al.
JOURNAL OF RHEUMATOLOGY (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
Daniel E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
Axel Finckh et al.
ARTHRITIS AND RHEUMATISM (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody
E. Solau-Gervais et al.
RHEUMATOLOGY (2006)
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
JJ Gomez-Reino et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
